Skip to main content
European Commission logo print header

Preclinical validation of a novel immunogenic composition to stimulate innate immunity

Objective

Immunotherapy is a promising approach to treat cancer and infectious diseases, but innovative approaches are required.
The cGAS-cGAMP-STING pathway can induce a potent immune response against viruses. It is also implicated in antitumoral immune responses that are effective. We have recently discovered that the small second messenger cGAMP can be packaged by viruses to stimulate immunity in target cells. We have developed methods to produce non-infectious virus-like particles containing cGAMP (cGAMP-VLPs) that strongly stimulate this innovative immune pathway. We will test the idea that cGAMP-VLPs are potent activators of anti-tumoral and anti-viral immunity. To reach this proof-of-concept, we
propose pre-clinical development plan in translational mouse models.

Host institution

INSTITUT CURIE
Net EU contribution
€ 150 000,00
Address
RUE D ULM 26
75231 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 150 000,00

Beneficiaries (1)